Form 4: West Pharmaceutical Services Director Robert Friel Reports Acquisition of Restricted Stock Units

Robert Friel, a director at West Pharmaceutical Services, reported the acquisition of 1,071 restricted stock units on May 6, 2025.

Summary

• On May 6, 2025, Robert Friel, a director of West Pharmaceutical Services Inc. [WST], acquired 1,071 shares of common stock in the form of restricted stock units.
• These restricted stock units were acquired at a price of $0.
• Following the transaction, Friel directly owns 4,681.98 shares of West Pharmaceutical Services Inc.
• The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
• Friel has a power of attorney designating Luis Cantarero, Louis Lalli, Ryan Metz and Caitlin Hippeli to act on his behalf for Section 16(a) filings.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

• The acquisition of restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

Industry Context

This is a standard SEC filing related to changes in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Comparison to Industry Standards

• Form 4 filings are a standard requirement for company insiders in the US, ensuring transparency in their trading activities.
• Similar filings are required for directors and officers of publicly listed companies in other countries, such as the UK and Canada.

Stakeholder Impact

• Shareholders are informed about changes in ownership by a company director.

Key Dates

Keywords

Form 4, West Pharmaceutical Services, Robert Friel, Director, Restricted Stock Units, Beneficial Ownership, Section 16(a), SEC Filing